Become a fan of Slashdot on Facebook

 



Forgot your password?
typodupeerror
×

Comment Re:RNA more sever, on paper (absent MSM) (Score 1) 191

The number of cases exclude any people that was not tested (e.g. when tests were hard to obtain, those without symptoms or another reason to test, those sharing a household with the positive, who often was assumed to be positive without a test and isolated accordingly)

(There are enough non-death effects though that avoiding getting it and reducing the severity through vaccination is likely still worth it) (And more importantly, it causes enough problems to overwhelm the medical systems to such a degree that people suffering from other diseases or injuries can't be treated if cases numbers are left to increase indefinitely with no attempts to mitigate the severity)

This estimates an IFR of between 0.1 and 1.5%, depending on the area. (It was likely a lot higher in the early days before treatments like dexamethasone, monoclonal antibodies, etc were figured out that what it is currently)

Comment Encourage users to move to other ISPs (Score 1) 127

It seems like encouraging users of those ISPs to move to others should quickly stop the demands. "In order to view content in HD, please using a different ISP" or surcharges for users of those ISPs.

The users pay for access to certain speeds. Charging the other side for it as well is unfair.

Comment Re:It is called "night" (Score 1) 287

Interconnecting grids might help coving some parts of the gaps... It might mean inefficient transmission over huge distances though...

Solar power is ideal for some things. Air conditioning, water hearing - air cons are often needed to counter the heating of the sun and water heating can easily be done any time of the day if the storage is decently insulated.

Using it for everything is much harder, but it might deal decently with the increase in load during the day, which helps if some sources don't like changing their output...

Comment Re:Reuse, don't recycle (Score 1) 64

Here sone of the Coca Cola bottlers now have returnable plastic bottles. (The 2l ones are new. Some of the 1l and 1.25l glass returnables were replaces with thicker plastic ones). It is the exception though and the vast majority of drink bottles can't be returned.

I'm not aware of any programs to reuse packaging for anything outside beverages either - shampoo, yogurt, condiments, etc...

Comment Reuse, don't recycle (Score 1) 64

It seems like making bottles a bit more durable and reusing them is much cleaner and economical than recycling or disposal...

(Standardising packaging would allow different brands to reuse each other's packaging as well, but that can be tricky...)

Reused bottles will reach end of life at some point though...

Submission + - FACEBOOK, INSTAGRAM AND WHATSAPP ALL GO DOWN IN MAJOR OUTAGE (independent.co.uk)

masikh writes: WhatsApp, Instagram and Facebook have all gone down in a major outage.

The three apps – which are all owned by Facebook, and run on shared infrastructure – all completely stopped working shortly before 5pm. Other products that are part of the same family of apps, such as Facebook Workplace, also stopped working.

Visitors to the Facebook website simply saw an error page or a message that their browser could not connect. The WhatsApp and Instagram apps continued to work, but did not show new content, including any messages sent or received during the problems....

Submission + - Meet Molnupiravir, Merck's Pill That Cuts COVID-19 Hospitalization and Death (arstechnica.com)

An anonymous reader writes: An oral antiviral drug appears to cut the risk of hospitalization and death from COVID-19 by roughly 50 percent in people newly diagnosed with the infection and at risk for severe disease, pharmaceutical company Merck announced Friday morning. The drug-maker and its partner, Ridgeback Biotherapeutics, released top-line results of a Phase III trial, which the companies ended early given the positive results. The companies say they will apply for an Emergency Use Authorization from the US Food and Drug Administration as soon as possible.

The trial enrolled people who had newly tested positive for a SARS-CoV-2 infection and had onset of mild-to-moderate COVID-19 symptoms within just the past five days of starting the trial. The enrollees also had to have at least one risk factor for a poor outcome, such as having obesity, diabetes, heart disease, or being age 60 or above. While some participants received a placebo and standard care, others took an oral dose of the drug every 12 hours for five days. After 29 days of follow-up, 53 out of 377 participants who received the placebo were hospitalized with COVID-19, and eight of those participants died. Among those who received the drug, only 28 of 385 were hospitalized and none of those patients died. Put another way, 7.3 percent of patients on the drug were either hospitalized or died compared with 14.1 percent in the placebo group. Merck also highlighted that the trial was global and that the drug appeared to work equally well against varying SARS-CoV-2 variants, including delta, gamma, and mu. The drug-maker noted that it had viral genetic data to identify variants from 40 percent of participants. The safety data was equally promising, with participants reporting similar numbers of drug-related adverse events between the placebo group than the drug group (11 percent and 12 percent, respectively). About 3.4 percent of people in the placebo group quit the study due to adverse events, while only 1.3 percent quit in the drug group.

The drug at the center of these seemingly smashing results is dubbed molnupiravir — a name inspired by that of Thor's hammer, Mjolnir. The idea is that the drug will strike down SARS-CoV-2, like a mighty blow from the god of thunder. In an interview with Stat news, Merck’s head of research and development, Dean Li, said that the new data proves the drug's mythological force. “Our prediction from our in vitro studies and now with this data is that molnupiravir is named after the right [thing]... this is a hammer against SARS-CoV-2 regardless of the variant.” Molnupiravir is a small molecule that wallops the work of a viral RNA-dependent RNA polymerase, an enzyme critical for making copies of RNA viruses, such as SARS-CoV-2. [...] Molnupiravir delivers a precise blow to viral RNA polymerase by posing as a building block for RNA. In the body, molnupiravir is forged into a deceptive ribonucleoside that the polymerase unwittingly incorporates into new strands of viral RNA instead of cytidine. This is essentially lethal. Researchers call the effect a "viral error catastrophe," in which the rate of genetic mutations or errors exceeds a threshold compatible with the virus surviving.

Comment Re:Repeat (Score 1) 11

This is the AWS hosted service (formerly "AWS ElasticSearch Service") based on OpenDistro for ElasticSearch adding OpenSearch and being renamed.

Slightly new, but certainly not unexpected after OpenDistro was renamed to OpenSearch (They basically changed the name and added OpenSearch 1.0 as an option)

Slashdot Top Deals

Work without a vision is slavery, Vision without work is a pipe dream, But vision with work is the hope of the world.

Working...